We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cytokine Required by Immune Cells in Lungs to Defend Against Pneumonia Infection

By LabMedica International staff writers
Posted on 09 Aug 2016
The cytokine macrophage-colony stimulating factor (M-CSF) was been found to play a critical role in the ability of immune cells in the lung to defend against infection by pneumonia-causing bacteria.

M-CSF is a hematopoietic growth factor that is involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells. More...
M-CSF affects macrophages and monocytes in several ways, including stimulating increased phagocytic and chemotactic activity, and increased tumor cell cytotoxicity.

To develop a better understanding of how M-CSF functions in the lungs, investigators at the University of Virginia (Charlottesville, USA) tested the hypothesis that M-CSF was required for mononuclear phagocyte-mediated host defenses during bacterial pneumonia in a mouse model of pneumonia infection.

They reported in the June 15, 2016, issue of The Journal of Immunology that in the mouse model system genetic deletion or immuno-neutralization of M-CSF resulted in reduced survival, increased bacterial burden, and greater lung injury. M-CSF was necessary for the expansion of lung mononuclear phagocytes during infection but did not affect the number of bone marrow or blood monocytes, proliferation of precursors, or recruitment of leukocytes to the lungs. In contrast, M-CSF was essential to the animals' survival and to antimicrobial functions of both lung and liver mononuclear phagocytes during pneumonia. The absence of M-CSF resulted in bacterial dissemination to the liver and hepatic necrosis.

"If you take M-CSF away, the infections get worse, so that raises two important questions about therapy: Would more be better? It may be that during infection, the body is making the right amount of M-CSF and if we add extra, it will not improve outcomes further," said senior author Dr. Borna Mehrad, associate professor of internal medicine and microbiology at the University of Virginia. "The second possibility is that there is room for improvement: in the fight between monocytes and the bacteria, M-CSF may make monocytes live longer and give them an edge. In addition, some people with weakened immunity might not make enough of M-CSF. If that is the case, you could augment that and improve their ability to fight the infection."

"We are interested in seeing if there are things we can do to strengthen the natural defenses of the host to help them fight the infection more effectively," said Dr. Mehrad. "Potentially this would be the sort of thing you could do in addition to antibiotics to help patients with severe infections."

Related Links:
University of Virginia



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.